DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess

doi:10.3389/fphar.2024.1470148

科研成果详情

题名	DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess
作者	Zhou, Qiang 1; Xie, Quanlei 2; Liu, Qiang 2; Wang, Haojie 1; Zhang, Zhan1; Yu, Zhao 3; Guo, Qian 4; Lin, Jie 1
发表日期	2024-10-02
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	DNA methylation inhibitors myelodysplastic syndromes WHO-vigiaccess retrospective descriptive analysis adverse reaction
其他关键词	ACUTE MYELOID-LEUKEMIA ; MYELODYSPLASTIC SYNDROMES ; AZACITIDINE ; DECITABINE ; 5-AZA-2'-DEOXYCYTIDINE
摘要	Introduction DNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders. This study evaluates the adverse drug reactions (ADRs) following the use of DNA methylation inhibitors in the World Health Organization (WHO) VigiAccess database and compares the characteristics of ADRs between the two drugs to select the drug with the minimum individualized risk for patients.Methods This study employed a retrospective descriptive analysis method. We compiled ADR reports for two marketed DNA methylation inhibitors for the treatment of MDS from WHO-VigiAccess. Data collected included demographic data such as age groups, gender, and regions of global patients covered by ADR reports, as well as data on the disease systems and symptoms caused by ADRs recorded in the annual reports and reports received by WHO. By calculating the proportion of ADRs reported for each drug, we compared the similarities and differences in ADRs between the two drugs.Results Overall, 23,763 adverse events (AEs) related to the two DNA methylation inhibitors were reported in VigiAccess. The results showed that the top 10 most common AEs were febrile neutropenia, bone marrow suppression, neutropenia, anemia, pancytopenia, leukopenia, thrombocytopenia, bone marrow failure, agranulocytosis, and hematotoxicity. The top five common types of DNA methylation inhibitor AEs were blood and lymphatic system disorders (11,178 cases, 47.0%), cardiac organ diseases (1,488 cases, 6.3%), various congenital familial genetic diseases (49 cases, 0.2%), ear and labyrinth diseases (100, 4.2%), and endocrine system diseases (57, 2.4%).Conclusion There is no Strong correlation between DNA methylation inhibitors and ADRs. Current comparative observational studies of these inhibitors show that there are common and specific adverse reactions in the ADR reports received by WHO for these drugs. Clinicians should improve the rational use of these drugs based on the characteristics of ADRs.
出版者	FRONTIERS MEDIA SA
ISSN	1663-9812
EISSN	1663-9812
卷号	15
DOI	10.3389/fphar.2024.1470148
页数	10
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:001331913300001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39415836
通讯作者地址	[Lin, Jie]Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Ruian Peoples Hosp, Wenzhou, Peoples R China. ; [Guo, Qian]Zhengzhou Univ, Affiliated Hosp 1, Dept Rhinol, Zhengzhou, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/220653
专题	第一临床医学院（信息与工程学院）、附属第一医院_药学部
通讯作者	Guo, Qian; Lin, Jie
作者单位	1.Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Ruian Peoples Hosp, Wenzhou, Peoples R China; 2.Nanchang Univ, Affiliated Hosp 1, Dept Vasc Surg, Nanchang, Peoples R China; 3.Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China; 4.Zhengzhou Univ, Affiliated Hosp 1, Dept Rhinol, Zhengzhou, Peoples R China
第一作者单位	第一临床医学院（信息与工程学院）、附属第一医院_药学部
通讯作者单位	第一临床医学院（信息与工程学院）、附属第一医院_药学部
第一作者的第一单位	第一临床医学院（信息与工程学院）、附属第一医院_药学部
推荐引用方式 GB/T 7714	Zhou, Qiang,Xie, Quanlei,Liu, Qiang,et al. DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess[J]. FRONTIERS IN PHARMACOLOGY,2024,15.
APA	Zhou, Qiang., Xie, Quanlei., Liu, Qiang., Wang, Haojie., Zhang, Zhan., ... & Lin, Jie. (2024). DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess. FRONTIERS IN PHARMACOLOGY, 15.
MLA	Zhou, Qiang,et al."DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess".FRONTIERS IN PHARMACOLOGY 15(2024).